Myelodysplastic syndrome (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Myelodysplastic syndrome" in English language version.

refsWebsite

Global rank English rank

66nih.gov

4^th place

47doi.org

2^nd place

11semanticscholar.org

11^th place

8^th place

7web.archive.org

1^st place

4lecturio.com

5,619^th place

2,948^th place

2cancer.gov

1,684^th place

1,350^th place

1rarediseases.org

5,181^st place

3,260^th place

1books.google.com

3^rd place

1worldcat.org

5^th place

1harvard.edu

18^th place

17^th place

1google.com

163^rd place

185^th place

1fda.gov

447^th place

338^th place

1handle.net

102^nd place

76^th place

1archive.org

6^th place

1clevelandclinicmeded.com

low place

1variety.com

13^th place

12^th place

1reuters.com

49^th place

47^th place

1journalnow.com

4,467^th place

2,455^th place

1latimes.com

22^nd place

19^th place

1tribuneindia.com

403^rd place

238^th place

1universetoday.com

3,691^st place

3,233^rd place

1nytimes.com

7^th place

1washingtonpost.com

34^th place

27^th place

archive.org

Kasper, Dennis L, Braunwald, Eugene, Fauci, Anthony, et al. (2005). Harrison's Principles of Internal Medicine (16th ed.). New York: McGraw-Hill. p. 625. ISBN 978-0-07-139140-5.

books.google.com

Hong WK, Holland JF (2010). Holland-Frei Cancer Medicine (8th ed.). PMPH-USA. p. 1544. ISBN 978-1-60795-014-1. Archived from the original on 27 October 2016.

cancer.gov

seer.cancer.gov

"Myelodysplasia". SEER. Archived from the original on 27 October 2016. Retrieved 27 October 2016.

cancer.gov

"Myelodysplastic Syndromes Treatment (PDQ®) – Patient Version". NCI. 12 August 2015. Archived from the original on 5 October 2016. Retrieved 27 October 2016.

clevelandclinicmeded.com

"Table 1: French-American-British (FAB) Classification of MDS". Archived from the original on 17 January 2006.

doi.org

Germing U, Kobbe G, Haas R, Gattermann N (November 2013). "Myelodysplastic syndromes: diagnosis, prognosis, and treatment". Deutsches Ärzteblatt International. 110 (46): 783–90. doi:10.3238/arztebl.2013.0783 (inactive 17 February 2025). PMC 3855821. PMID 24300826.{{cite journal}}: CS1 maint: DOI inactive as of February 2025 (link)
Hasserjian RP, Germing U, Malcovati L (December 2023). "Diagnosis and classification of myelodysplastic syndromes". Blood. 142 (26): 2247–57. doi:10.1182/blood.2023020078. PMID 37774372.
Patnaik MM, Lasho T (4 December 2020). "Evidence-Based Minireview: Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review". Hematology. 2020 (1): 460–4. doi:10.1182/hematology.2020000163. PMC 7727594. PMID 33275673.
Sperling AS, Leventhal M, Gibson CJ, Ebert BL, Steensma DP (March 2020). "Myelodysplastic syndromes (MDS) occurring in Agent Orange exposed individuals carry a mutational spectrum similar to that of de novo MDS". Leuk Lymphoma. 61 (3): 728–731. doi:10.1080/10428194.2019.1689394. PMC 7268906. PMID 31714164.
Iwanaga M, Hsu WL, Soda M, Takasaki Y, Tawara M, Joh T, et al. (February 2011). "Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors". Journal of Clinical Oncology. 29 (4): 428–34. doi:10.1200/JCO.2010.31.3080. PMID 21149671.
Dokal I, Vulliamy T (August 2010). "Inherited bone marrow failure syndromes". Haematologica. 95 (8): 1236–40. doi:10.3324/haematol.2010.025619. PMC 2913069. PMID 20675743.
Hall T, Gurbuxani S, Crispino JD (May 2024). "Malignant progression of preleukemic disorders". Blood. 143 (22): 2245–55. doi:10.1182/blood.2023020817. PMC 11181356. PMID 38498034.
Bejar R (December 2018). "What biologic factors predict for transformation to AML?". Best Practice & Research. Clinical Haematology. 31 (4): 341–5. doi:10.1016/j.beha.2018.10.002. PMID 30466744. S2CID 53712886.
Wolach O, Stone RM (2015). "How I treat mixed-phenotype acute leukemia". Blood. 125 (16): 2477–85. doi:10.1182/blood-2014-10-551465. PMID 25605373.
Cazzola M, Invernizzi R, Bergamaschi G, Levi S, Corsi B, Travaglino E, et al. (March 2003). "Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia". Blood. 101 (5): 1996–2000. doi:10.1182/blood-2002-07-2006. PMID 12406866. S2CID 5729203.
Zhou T, Chen P, Gu J, Bishop AJ, Scott LM, Hasty P, et al. (January 2015). "Potential relationship between inadequate response to DNA damage and development of myelodysplastic syndrome". Int J Mol Sci. 16 (1): 966–89. doi:10.3390/ijms16010966. PMC 4307285. PMID 25569081.
Zhou T, Hasty P, Walter CA, Bishop AJ, Scott LM, Rebel VI (August 2013). "Myelodysplastic syndrome: an inability to appropriately respond to damaged DNA?". Exp Hematol. 41 (8): 665–74. doi:10.1016/j.exphem.2013.04.008. PMC 3729593. PMID 23643835.
Jankowska AM, Gondek LP, Szpurka H, Nearman ZP, Tiu RV, Maciejewski JP (March 2008). "Base excision repair dysfunction in a subgroup of patients with myelodysplastic syndrome". Leukemia. 22 (3): 551–8. doi:10.1038/sj.leu.2405055. PMID 18059482.
Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G (October 1974). "Distinct haematological disorder with deletion of long arm of no. 5 chromosome". Nature. 251 (5474): 437–38. Bibcode:1974Natur.251..437V. doi:10.1038/251437a0. PMID 4421285. S2CID 4286311.
List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, et al. (February 2005). "Efficacy of lenalidomide in myelodysplastic syndromes". The New England Journal of Medicine. 352 (6): 549–57. doi:10.1056/NEJMoa041668. PMID 15703420.
Rozovski U, Keating M, Estrov Z (July 2013). "The significance of spliceosome mutations in chronic lymphocytic leukemia". Leuk Lymphoma. 54 (7): 1364–6. doi:10.3109/10428194.2012.742528. PMC 4176818. PMID 23270583.
Molenaar RJ, Radivoyevitch T, Maciejewski JP, van Noorden CJ, Bleeker FE (December 2014). "The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation". Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1846 (2): 326–41. doi:10.1016/j.bbcan.2014.05.004. PMID 24880135.
Molenaar RJ, Thota S, Nagata Y, Patel B, Clemente M, Przychodzen B, et al. (November 2015). "Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms". Leukemia. 29 (11): 2134–42. doi:10.1038/leu.2015.91. PMC 5821256. PMID 25836588.
Crispino JD, Horwitz MS (April 2017). "GATA factor mutations in hematologic disease". Blood. 129 (15): 2103–10. doi:10.1182/blood-2016-09-687889. PMC 5391620. PMID 28179280.
Hirabayashi S, Wlodarski MW, Kozyra E, Niemeyer CM (August 2017). "Heterogeneity of GATA2-related myeloid neoplasms". International Journal of Hematology. 106 (2): 175–82. doi:10.1007/s12185-017-2285-2. PMID 28643018.
Takasaki K, Chou ST (2024). "GATA1 in Normal and Pathologic Megakaryopoiesis and Platelet Development". Transcription factors in blood cell development. Adv Exp Med Biol. Vol. 1459. pp. 261–287. doi:10.1007/978-3-031-62731-6_12. ISBN 978-3-031-62730-9. PMID 39017848.
Bhatnagar N, Nizery L, Tunstall O, Vyas P, Roberts I (October 2016). "Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update". Current Hematologic Malignancy Reports. 11 (5): 333–41. doi:10.1007/s11899-016-0338-x. PMC 5031718. PMID 27510823.
Seewald L, Taub JW, Maloney KW, McCabe ER (September 2012). "Acute leukemias in children with Down syndrome". Molecular Genetics and Metabolism. 107 (1–2): 25–30. doi:10.1016/j.ymgme.2012.07.011. PMID 22867885.
Mecham B, Drissi W, Brummell G, Dadi N, Martin DE (May 2024). "Severe B12 Deficiency Causing a Maturation Defect Mimicking Myelodysplastic Syndrome With Excess Blasts". Cureus. 16 (5): e60837. doi:10.7759/cureus.60837. PMC 11191413. PMID 38910768.
Sekeres MA, Taylor J (6 September 2022). "Diagnosis and Treatment of Myelodysplastic Syndromes: A Review". JAMA. 328 (9): 872–880. doi:10.1001/jama.2022.14578. PMID 36066514.
Gondek LP, Tiu R, O'Keefe CL, Sekeres MA, Theil KS, Maciejewski JP (February 2008). "Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML". Blood. 111 (3): 1534–42. doi:10.1182/blood-2007-05-092304. PMC 2214746. PMID 17954704.
Huff JD, Keung YK, Thakuri M, Beaty MW, Hurd DD, Owen J, et al. (July 2007). "Copper deficiency causes reversible myelodysplasia". American Journal of Hematology. 82 (7): 625–30. doi:10.1002/ajh.20864. PMID 17236184. S2CID 44398996.
Luo T, Zurko J, Astle J, Shah NN (2021). "Mimicking Myelodysplastic Syndrome: Importance of Differential Diagnosis". Case Rep Hematol. 2021: 9661765. doi:10.1155/2021/9661765. PMC 8648467. PMID 34881068.
Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. (September 2022). "International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data". Blood. 140 (11): 1200–28. doi:10.1182/blood.2022015850. PMC 9479031. PMID 35767897.
DeZern AE, Malcovati L, Ebert BL (January 2019). "CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice". Am Soc Clin Oncol Educ Book. 39 (39): 400–410. doi:10.1200/EDBK_239083. PMID 31099654.
Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Pérez WS, Anasetti C, et al. (July 2004). "A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome". Blood. 104 (2): 579–85. doi:10.1182/blood-2004-01-0338. PMID 15039286. S2CID 17907118.
Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, Nannya Y, et al. (July 2022). "Molecular International Prognostic Scoring System for Myelodysplastic Syndromes". NEJM Evid. 1 (7): EVIDoa2200008. doi:10.1056/EVIDoa2200008. PMID 38319256.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. (March 2009). "Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study". The Lancet Oncology. 10 (3): 223–232. doi:10.1016/S1470-2045(09)70003-8. PMC 4086808. PMID 19230772.
Kantarjian HM, O'Brien S, Shan J, Aribi A, Garcia-Manero G, Jabbour E, et al. (January 2007). "Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome". Cancer. 109 (2): 265–73. doi:10.1002/cncr.22376. PMID 17133405. S2CID 41205800.
Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, et al. (April 2006). "Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study". Cancer. 106 (8): 1794–803. doi:10.1002/cncr.21792. PMID 16532500. S2CID 9556660.
Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, et al. (January 2007). "Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia". Blood. 109 (1): 52–57. doi:10.1182/blood-2006-05-021162. PMID 16882708.
List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. (October 2006). "Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion". The New England Journal of Medicine. 355 (14): 1456–65. doi:10.1056/NEJMoa061292. PMID 17021321.
Fenaux P, Platzbecker U, Mufti GJ (9 January 2020). "Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes". New England Journal of Medicine. 382 (2): 140–151. doi:10.1056/NEJMoa1908892. hdl:2158/1193441. PMID 31914241.
Hellström-Lindberg ES, Kröger N (December 2023). "Clinical decision-making and treatment of myelodysplastic syndromes". Blood. 142 (26): 2268–81. doi:10.1182/blood.2023020079. PMID 37874917.
Oosterveld M, Wittebol SH, Lemmens WA, Kiemeney BA, Catik A, Muus P, et al. (October 2003). "The impact of intensive antileukaemic treatment strategies on prognosis of myelodysplastic syndrome patients aged less than 61 years according to International Prognostic Scoring System risk groups". British Journal of Haematology. 123 (1): 81–89. doi:10.1046/j.1365-2141.2003.04544.x. PMID 14510946. S2CID 24037285.
Parisi S, Finelli C (December 2021). "Prognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients". Journal of Blood Medicine. 12: 1019–30. doi:10.2147/JBM.S287876. PMC 8651046. PMID 34887690.
Solé F, Espinet B, Sanz GF, Cervera J, Calasanz MJ, Luño E, et al. (February 2000). "Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Español de Citogenética Hematológica". British Journal of Haematology. 108 (2): 346–56. doi:10.1046/j.1365-2141.2000.01868.x. PMID 10691865. S2CID 10149222.
Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. (March 1997). "International scoring system for evaluating prognosis in myelodysplastic syndromes". Blood. 89 (6): 2079–88. doi:10.1182/blood.V89.6.2079. PMID 9058730.
DeZern AE, Greenberg PL (December 2023). "The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes". Blood. 142 (26): 2258–67. doi:10.1182/blood.2023020081. PMID 37562001.
Aul C, Giagounidis A, Germing U (June 2001). "Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics". International Journal of Hematology. 73 (4): 405–10. doi:10.1007/BF02994001. PMID 11503953. S2CID 24340387.
Block M, Jacobson LO, Bethard WF (July 1953). "Preleukemic acute human leukemia". Journal of the American Medical Association. 152 (11): 1018–28. doi:10.1001/jama.1953.03690110032010. PMID 13052490.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. (August 1976). "Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group". British Journal of Haematology. 33 (4): 451–58. doi:10.1111/j.1365-2141.1976.tb03563.x. PMID 188440. S2CID 9985915.

fda.gov

"FDA Approves New Therapy for Myelodysplastic Syndromes (MDS) That Can Be Taken at Home". U.S. Food and Drug Administration (FDA) (Press release). 7 July 2020. Retrieved 7 July 2020. This article incorporates text from this source, which is in the public domain.

google.com

"Rudhiram Hematology Clinic - Google Search". www.google.com. Retrieved 3 February 2022.

handle.net

hdl.handle.net

Fenaux P, Platzbecker U, Mufti GJ (9 January 2020). "Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes". New England Journal of Medicine. 382 (2): 140–151. doi:10.1056/NEJMoa1908892. hdl:2158/1193441. PMID 31914241.

harvard.edu

ui.adsabs.harvard.edu

Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G (October 1974). "Distinct haematological disorder with deletion of long arm of no. 5 chromosome". Nature. 251 (5474): 437–38. Bibcode:1974Natur.251..437V. doi:10.1038/251437a0. PMID 4421285. S2CID 4286311.

journalnow.com

Staff J (4 January 2009). "Veteran actor Pat Hingle dies at 84 in NC home". Winston-Salem Journal.

latimes.com

McClellan D (24 November 2011). "Paul Motian dies at 80; jazz drummer and composer". Los Angeles Times. Archived from the original on 14 April 2016. Retrieved 22 February 2020.

lecturio.com

"Anemia: Overview". The Lecturio Medical Concept Library. Retrieved 15 August 2021.
"Neutropenia". The Lecturio Medical Concept Library. Retrieved 15 August 2021.
"Thrombocytopenia". The Lecturio Medical Concept Library. Retrieved 15 August 2021.
"Myelodysplastic Syndromes". The Lecturio Medical Concept Library. Retrieved 11 August 2021.

nih.gov

pubmed.ncbi.nlm.nih.gov

Germing U, Kobbe G, Haas R, Gattermann N (November 2013). "Myelodysplastic syndromes: diagnosis, prognosis, and treatment". Deutsches Ärzteblatt International. 110 (46): 783–90. doi:10.3238/arztebl.2013.0783 (inactive 17 February 2025). PMC 3855821. PMID 24300826.{{cite journal}}: CS1 maint: DOI inactive as of February 2025 (link)
Hasserjian RP, Germing U, Malcovati L (December 2023). "Diagnosis and classification of myelodysplastic syndromes". Blood. 142 (26): 2247–57. doi:10.1182/blood.2023020078. PMID 37774372.
Patnaik MM, Lasho T (4 December 2020). "Evidence-Based Minireview: Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review". Hematology. 2020 (1): 460–4. doi:10.1182/hematology.2020000163. PMC 7727594. PMID 33275673.
Sperling AS, Leventhal M, Gibson CJ, Ebert BL, Steensma DP (March 2020). "Myelodysplastic syndromes (MDS) occurring in Agent Orange exposed individuals carry a mutational spectrum similar to that of de novo MDS". Leuk Lymphoma. 61 (3): 728–731. doi:10.1080/10428194.2019.1689394. PMC 7268906. PMID 31714164.
Iwanaga M, Hsu WL, Soda M, Takasaki Y, Tawara M, Joh T, et al. (February 2011). "Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors". Journal of Clinical Oncology. 29 (4): 428–34. doi:10.1200/JCO.2010.31.3080. PMID 21149671.
Dokal I, Vulliamy T (August 2010). "Inherited bone marrow failure syndromes". Haematologica. 95 (8): 1236–40. doi:10.3324/haematol.2010.025619. PMC 2913069. PMID 20675743.
Hall T, Gurbuxani S, Crispino JD (May 2024). "Malignant progression of preleukemic disorders". Blood. 143 (22): 2245–55. doi:10.1182/blood.2023020817. PMC 11181356. PMID 38498034.
Bejar R (December 2018). "What biologic factors predict for transformation to AML?". Best Practice & Research. Clinical Haematology. 31 (4): 341–5. doi:10.1016/j.beha.2018.10.002. PMID 30466744. S2CID 53712886.
Rasel M, Mahboobi SK (2022), "Transfusion Iron Overload", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 32965817, retrieved 3 February 2022
Wolach O, Stone RM (2015). "How I treat mixed-phenotype acute leukemia". Blood. 125 (16): 2477–85. doi:10.1182/blood-2014-10-551465. PMID 25605373.
Cazzola M, Invernizzi R, Bergamaschi G, Levi S, Corsi B, Travaglino E, et al. (March 2003). "Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia". Blood. 101 (5): 1996–2000. doi:10.1182/blood-2002-07-2006. PMID 12406866. S2CID 5729203.
Zhou T, Chen P, Gu J, Bishop AJ, Scott LM, Hasty P, et al. (January 2015). "Potential relationship between inadequate response to DNA damage and development of myelodysplastic syndrome". Int J Mol Sci. 16 (1): 966–89. doi:10.3390/ijms16010966. PMC 4307285. PMID 25569081.
Zhou T, Hasty P, Walter CA, Bishop AJ, Scott LM, Rebel VI (August 2013). "Myelodysplastic syndrome: an inability to appropriately respond to damaged DNA?". Exp Hematol. 41 (8): 665–74. doi:10.1016/j.exphem.2013.04.008. PMC 3729593. PMID 23643835.
Jankowska AM, Gondek LP, Szpurka H, Nearman ZP, Tiu RV, Maciejewski JP (March 2008). "Base excision repair dysfunction in a subgroup of patients with myelodysplastic syndrome". Leukemia. 22 (3): 551–8. doi:10.1038/sj.leu.2405055. PMID 18059482.
Bunn HF (November 1986). "5q- and disordered haematopoiesis". Clinics in Haematology. 15 (4): 1023–35. PMID 3552346.
Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G (October 1974). "Distinct haematological disorder with deletion of long arm of no. 5 chromosome". Nature. 251 (5474): 437–38. Bibcode:1974Natur.251..437V. doi:10.1038/251437a0. PMID 4421285. S2CID 4286311.
List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, et al. (February 2005). "Efficacy of lenalidomide in myelodysplastic syndromes". The New England Journal of Medicine. 352 (6): 549–57. doi:10.1056/NEJMoa041668. PMID 15703420.
Rozovski U, Keating M, Estrov Z (July 2013). "The significance of spliceosome mutations in chronic lymphocytic leukemia". Leuk Lymphoma. 54 (7): 1364–6. doi:10.3109/10428194.2012.742528. PMC 4176818. PMID 23270583.
Molenaar RJ, Radivoyevitch T, Maciejewski JP, van Noorden CJ, Bleeker FE (December 2014). "The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation". Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1846 (2): 326–41. doi:10.1016/j.bbcan.2014.05.004. PMID 24880135.
Molenaar RJ, Thota S, Nagata Y, Patel B, Clemente M, Przychodzen B, et al. (November 2015). "Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms". Leukemia. 29 (11): 2134–42. doi:10.1038/leu.2015.91. PMC 5821256. PMID 25836588.
Crispino JD, Horwitz MS (April 2017). "GATA factor mutations in hematologic disease". Blood. 129 (15): 2103–10. doi:10.1182/blood-2016-09-687889. PMC 5391620. PMID 28179280.
Hirabayashi S, Wlodarski MW, Kozyra E, Niemeyer CM (August 2017). "Heterogeneity of GATA2-related myeloid neoplasms". International Journal of Hematology. 106 (2): 175–82. doi:10.1007/s12185-017-2285-2. PMID 28643018.
Takasaki K, Chou ST (2024). "GATA1 in Normal and Pathologic Megakaryopoiesis and Platelet Development". Transcription factors in blood cell development. Adv Exp Med Biol. Vol. 1459. pp. 261–287. doi:10.1007/978-3-031-62731-6_12. ISBN 978-3-031-62730-9. PMID 39017848.
Bhatnagar N, Nizery L, Tunstall O, Vyas P, Roberts I (October 2016). "Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update". Current Hematologic Malignancy Reports. 11 (5): 333–41. doi:10.1007/s11899-016-0338-x. PMC 5031718. PMID 27510823.
Seewald L, Taub JW, Maloney KW, McCabe ER (September 2012). "Acute leukemias in children with Down syndrome". Molecular Genetics and Metabolism. 107 (1–2): 25–30. doi:10.1016/j.ymgme.2012.07.011. PMID 22867885.
Mecham B, Drissi W, Brummell G, Dadi N, Martin DE (May 2024). "Severe B12 Deficiency Causing a Maturation Defect Mimicking Myelodysplastic Syndrome With Excess Blasts". Cureus. 16 (5): e60837. doi:10.7759/cureus.60837. PMC 11191413. PMID 38910768.
Sekeres MA, Taylor J (6 September 2022). "Diagnosis and Treatment of Myelodysplastic Syndromes: A Review". JAMA. 328 (9): 872–880. doi:10.1001/jama.2022.14578. PMID 36066514.
Gondek LP, Tiu R, O'Keefe CL, Sekeres MA, Theil KS, Maciejewski JP (February 2008). "Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML". Blood. 111 (3): 1534–42. doi:10.1182/blood-2007-05-092304. PMC 2214746. PMID 17954704.
Huff JD, Keung YK, Thakuri M, Beaty MW, Hurd DD, Owen J, et al. (July 2007). "Copper deficiency causes reversible myelodysplasia". American Journal of Hematology. 82 (7): 625–30. doi:10.1002/ajh.20864. PMID 17236184. S2CID 44398996.
Luo T, Zurko J, Astle J, Shah NN (2021). "Mimicking Myelodysplastic Syndrome: Importance of Differential Diagnosis". Case Rep Hematol. 2021: 9661765. doi:10.1155/2021/9661765. PMC 8648467. PMID 34881068.
Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. (September 2022). "International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data". Blood. 140 (11): 1200–28. doi:10.1182/blood.2022015850. PMC 9479031. PMID 35767897.
DeZern AE, Malcovati L, Ebert BL (January 2019). "CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice". Am Soc Clin Oncol Educ Book. 39 (39): 400–410. doi:10.1200/EDBK_239083. PMID 31099654.
Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Pérez WS, Anasetti C, et al. (July 2004). "A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome". Blood. 104 (2): 579–85. doi:10.1182/blood-2004-01-0338. PMID 15039286. S2CID 17907118.
Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, Nannya Y, et al. (July 2022). "Molecular International Prognostic Scoring System for Myelodysplastic Syndromes". NEJM Evid. 1 (7): EVIDoa2200008. doi:10.1056/EVIDoa2200008. PMID 38319256.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. (March 2009). "Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study". The Lancet Oncology. 10 (3): 223–232. doi:10.1016/S1470-2045(09)70003-8. PMC 4086808. PMID 19230772.
Kantarjian HM, O'Brien S, Shan J, Aribi A, Garcia-Manero G, Jabbour E, et al. (January 2007). "Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome". Cancer. 109 (2): 265–73. doi:10.1002/cncr.22376. PMID 17133405. S2CID 41205800.
Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, et al. (April 2006). "Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study". Cancer. 106 (8): 1794–803. doi:10.1002/cncr.21792. PMID 16532500. S2CID 9556660.
Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, et al. (January 2007). "Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia". Blood. 109 (1): 52–57. doi:10.1182/blood-2006-05-021162. PMID 16882708.
List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. (October 2006). "Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion". The New England Journal of Medicine. 355 (14): 1456–65. doi:10.1056/NEJMoa061292. PMID 17021321.
Fenaux P, Platzbecker U, Mufti GJ (9 January 2020). "Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes". New England Journal of Medicine. 382 (2): 140–151. doi:10.1056/NEJMoa1908892. hdl:2158/1193441. PMID 31914241.
Hellström-Lindberg ES, Kröger N (December 2023). "Clinical decision-making and treatment of myelodysplastic syndromes". Blood. 142 (26): 2268–81. doi:10.1182/blood.2023020079. PMID 37874917.
Oosterveld M, Wittebol SH, Lemmens WA, Kiemeney BA, Catik A, Muus P, et al. (October 2003). "The impact of intensive antileukaemic treatment strategies on prognosis of myelodysplastic syndrome patients aged less than 61 years according to International Prognostic Scoring System risk groups". British Journal of Haematology. 123 (1): 81–89. doi:10.1046/j.1365-2141.2003.04544.x. PMID 14510946. S2CID 24037285.
Parisi S, Finelli C (December 2021). "Prognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients". Journal of Blood Medicine. 12: 1019–30. doi:10.2147/JBM.S287876. PMC 8651046. PMID 34887690.
Solé F, Espinet B, Sanz GF, Cervera J, Calasanz MJ, Luño E, et al. (February 2000). "Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Español de Citogenética Hematológica". British Journal of Haematology. 108 (2): 346–56. doi:10.1046/j.1365-2141.2000.01868.x. PMID 10691865. S2CID 10149222.
Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. (March 1997). "International scoring system for evaluating prognosis in myelodysplastic syndromes". Blood. 89 (6): 2079–88. doi:10.1182/blood.V89.6.2079. PMID 9058730.
DeZern AE, Greenberg PL (December 2023). "The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes". Blood. 142 (26): 2258–67. doi:10.1182/blood.2023020081. PMID 37562001.
Aul C, Giagounidis A, Germing U (June 2001). "Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics". International Journal of Hematology. 73 (4): 405–10. doi:10.1007/BF02994001. PMID 11503953. S2CID 24340387.
Block M, Jacobson LO, Bethard WF (July 1953). "Preleukemic acute human leukemia". Journal of the American Medical Association. 152 (11): 1018–28. doi:10.1001/jama.1953.03690110032010. PMID 13052490.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. (August 1976). "Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group". British Journal of Haematology. 33 (4): 451–58. doi:10.1111/j.1365-2141.1976.tb03563.x. PMID 188440. S2CID 9985915.

ncbi.nlm.nih.gov

Germing U, Kobbe G, Haas R, Gattermann N (November 2013). "Myelodysplastic syndromes: diagnosis, prognosis, and treatment". Deutsches Ärzteblatt International. 110 (46): 783–90. doi:10.3238/arztebl.2013.0783 (inactive 17 February 2025). PMC 3855821. PMID 24300826.{{cite journal}}: CS1 maint: DOI inactive as of February 2025 (link)
Patnaik MM, Lasho T (4 December 2020). "Evidence-Based Minireview: Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review". Hematology. 2020 (1): 460–4. doi:10.1182/hematology.2020000163. PMC 7727594. PMID 33275673.
Sperling AS, Leventhal M, Gibson CJ, Ebert BL, Steensma DP (March 2020). "Myelodysplastic syndromes (MDS) occurring in Agent Orange exposed individuals carry a mutational spectrum similar to that of de novo MDS". Leuk Lymphoma. 61 (3): 728–731. doi:10.1080/10428194.2019.1689394. PMC 7268906. PMID 31714164.
Dokal I, Vulliamy T (August 2010). "Inherited bone marrow failure syndromes". Haematologica. 95 (8): 1236–40. doi:10.3324/haematol.2010.025619. PMC 2913069. PMID 20675743.
Rasel M, Mahboobi SK (2022), "Transfusion Iron Overload", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 32965817, retrieved 3 February 2022
Zhou T, Chen P, Gu J, Bishop AJ, Scott LM, Hasty P, et al. (January 2015). "Potential relationship between inadequate response to DNA damage and development of myelodysplastic syndrome". Int J Mol Sci. 16 (1): 966–89. doi:10.3390/ijms16010966. PMC 4307285. PMID 25569081.
Zhou T, Hasty P, Walter CA, Bishop AJ, Scott LM, Rebel VI (August 2013). "Myelodysplastic syndrome: an inability to appropriately respond to damaged DNA?". Exp Hematol. 41 (8): 665–74. doi:10.1016/j.exphem.2013.04.008. PMC 3729593. PMID 23643835.
Rozovski U, Keating M, Estrov Z (July 2013). "The significance of spliceosome mutations in chronic lymphocytic leukemia". Leuk Lymphoma. 54 (7): 1364–6. doi:10.3109/10428194.2012.742528. PMC 4176818. PMID 23270583.
Molenaar RJ, Thota S, Nagata Y, Patel B, Clemente M, Przychodzen B, et al. (November 2015). "Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms". Leukemia. 29 (11): 2134–42. doi:10.1038/leu.2015.91. PMC 5821256. PMID 25836588.
Crispino JD, Horwitz MS (April 2017). "GATA factor mutations in hematologic disease". Blood. 129 (15): 2103–10. doi:10.1182/blood-2016-09-687889. PMC 5391620. PMID 28179280.
Bhatnagar N, Nizery L, Tunstall O, Vyas P, Roberts I (October 2016). "Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update". Current Hematologic Malignancy Reports. 11 (5): 333–41. doi:10.1007/s11899-016-0338-x. PMC 5031718. PMID 27510823.
Mecham B, Drissi W, Brummell G, Dadi N, Martin DE (May 2024). "Severe B12 Deficiency Causing a Maturation Defect Mimicking Myelodysplastic Syndrome With Excess Blasts". Cureus. 16 (5): e60837. doi:10.7759/cureus.60837. PMC 11191413. PMID 38910768.
Gondek LP, Tiu R, O'Keefe CL, Sekeres MA, Theil KS, Maciejewski JP (February 2008). "Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML". Blood. 111 (3): 1534–42. doi:10.1182/blood-2007-05-092304. PMC 2214746. PMID 17954704.
Luo T, Zurko J, Astle J, Shah NN (2021). "Mimicking Myelodysplastic Syndrome: Importance of Differential Diagnosis". Case Rep Hematol. 2021: 9661765. doi:10.1155/2021/9661765. PMC 8648467. PMID 34881068.
Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. (September 2022). "International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data". Blood. 140 (11): 1200–28. doi:10.1182/blood.2022015850. PMC 9479031. PMID 35767897.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. (March 2009). "Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study". The Lancet Oncology. 10 (3): 223–232. doi:10.1016/S1470-2045(09)70003-8. PMC 4086808. PMID 19230772.
Parisi S, Finelli C (December 2021). "Prognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients". Journal of Blood Medicine. 12: 1019–30. doi:10.2147/JBM.S287876. PMC 8651046. PMID 34887690.

nytimes.com

"Illness as More Than Metaphor". The New York Times Magazine. 4 December 2005. Retrieved 18 December 2017.

rarediseases.org

"Myelodysplastic Syndromes". NORD (National Organization for Rare Disorders). Retrieved 23 May 2019.

reuters.com

"Panama says President Cortizo still in remission from rare blood disorder". Reuters. 6 December 2023. Retrieved 6 December 2023.

semanticscholar.org

api.semanticscholar.org

Bejar R (December 2018). "What biologic factors predict for transformation to AML?". Best Practice & Research. Clinical Haematology. 31 (4): 341–5. doi:10.1016/j.beha.2018.10.002. PMID 30466744. S2CID 53712886.
Cazzola M, Invernizzi R, Bergamaschi G, Levi S, Corsi B, Travaglino E, et al. (March 2003). "Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia". Blood. 101 (5): 1996–2000. doi:10.1182/blood-2002-07-2006. PMID 12406866. S2CID 5729203.
Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G (October 1974). "Distinct haematological disorder with deletion of long arm of no. 5 chromosome". Nature. 251 (5474): 437–38. Bibcode:1974Natur.251..437V. doi:10.1038/251437a0. PMID 4421285. S2CID 4286311.
Huff JD, Keung YK, Thakuri M, Beaty MW, Hurd DD, Owen J, et al. (July 2007). "Copper deficiency causes reversible myelodysplasia". American Journal of Hematology. 82 (7): 625–30. doi:10.1002/ajh.20864. PMID 17236184. S2CID 44398996.
Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Pérez WS, Anasetti C, et al. (July 2004). "A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome". Blood. 104 (2): 579–85. doi:10.1182/blood-2004-01-0338. PMID 15039286. S2CID 17907118.
Kantarjian HM, O'Brien S, Shan J, Aribi A, Garcia-Manero G, Jabbour E, et al. (January 2007). "Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome". Cancer. 109 (2): 265–73. doi:10.1002/cncr.22376. PMID 17133405. S2CID 41205800.
Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, et al. (April 2006). "Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study". Cancer. 106 (8): 1794–803. doi:10.1002/cncr.21792. PMID 16532500. S2CID 9556660.
Oosterveld M, Wittebol SH, Lemmens WA, Kiemeney BA, Catik A, Muus P, et al. (October 2003). "The impact of intensive antileukaemic treatment strategies on prognosis of myelodysplastic syndrome patients aged less than 61 years according to International Prognostic Scoring System risk groups". British Journal of Haematology. 123 (1): 81–89. doi:10.1046/j.1365-2141.2003.04544.x. PMID 14510946. S2CID 24037285.
Solé F, Espinet B, Sanz GF, Cervera J, Calasanz MJ, Luño E, et al. (February 2000). "Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Español de Citogenética Hematológica". British Journal of Haematology. 108 (2): 346–56. doi:10.1046/j.1365-2141.2000.01868.x. PMID 10691865. S2CID 10149222.
Aul C, Giagounidis A, Germing U (June 2001). "Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics". International Journal of Hematology. 73 (4): 405–10. doi:10.1007/BF02994001. PMID 11503953. S2CID 24340387.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. (August 1976). "Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group". British Journal of Haematology. 33 (4): 451–58. doi:10.1111/j.1365-2141.1976.tb03563.x. PMID 188440. S2CID 9985915.

tribuneindia.com

"The Tribune, Chandigarh, India – Main News". Tribuneindia.com. Archived from the original on 11 December 2008. Retrieved 21 June 2019.

universetoday.com

"Remembering Carl Sagan". Universe Today. 9 November 2012. Archived from the original on 12 March 2017. Retrieved 10 March 2017.

variety.com

"Saxophonist Brecker dies from MDS". Variety. 14 January 2007. Retrieved 23 September 2018.

washingtonpost.com

https://www.washingtonpost.com/arts-entertainment/2022/05/29/norm-macdonald-nothing-special-netflix/

web.archive.org

"Myelodysplasia". SEER. Archived from the original on 27 October 2016. Retrieved 27 October 2016.
"Myelodysplastic Syndromes Treatment (PDQ®) – Patient Version". NCI. 12 August 2015. Archived from the original on 5 October 2016. Retrieved 27 October 2016.
Hong WK, Holland JF (2010). Holland-Frei Cancer Medicine (8th ed.). PMPH-USA. p. 1544. ISBN 978-1-60795-014-1. Archived from the original on 27 October 2016.
"Table 1: French-American-British (FAB) Classification of MDS". Archived from the original on 17 January 2006.
McClellan D (24 November 2011). "Paul Motian dies at 80; jazz drummer and composer". Los Angeles Times. Archived from the original on 14 April 2016. Retrieved 22 February 2020.
"The Tribune, Chandigarh, India – Main News". Tribuneindia.com. Archived from the original on 11 December 2008. Retrieved 21 June 2019.
"Remembering Carl Sagan". Universe Today. 9 November 2012. Archived from the original on 12 March 2017. Retrieved 10 March 2017.

worldcat.org

search.worldcat.org

Myelodysplastic Syndrome. White Plains, NY: The Leukemia & Lymphoma Society. 2001. p. 24. OCLC 64551506.